BillionToOne
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1035 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 460-2551Website
www.billiontoone.comRevenue
$354.5 MillionStock Symbol
BLLNIndustry
ZI Rank: 4
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
5
4
1
2
2
4
About BillionToOne
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.Explore more
BillionToOne Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BillionToOne your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BillionToOne recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BillionToOne has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BillionToOne launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BillionToOne has new funding data
Check out if BillionToOne is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at BillionToOne
BillionToOne, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BillionToOne had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined BillionToOne as Masked Content
Find 3 more new buyers
Compare Similar Companies to BillionToOne
Compare insights from companies similar to BillionToOne, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$12.9M
201-500
Private
-
2000
Company Profile Activity
Activity Insights
BillionToOne is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BillionToOne is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BillionToOne.
BillionToOne financials insights
Gather financial insights about BillionToOne, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$55M
2022
Series C
$125M
Unspecified
$48.5M
2024
Series D
$130M
2025
IPO
$273.1M
BillionToOne Tech Stack
A closer look at the technologies used by BillionToOne
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Earnings, Contracts, Finance, Financial Transactions
Open Position
Open Position
BillionToOne News & Media
BillionToOne CTO sells shares, exercises options | BLLN Insider Trading - Stock Titan
CTO David Tsao sold 20,000 BillionToOne Class A shares and exercised options for 20,000 shares at $2.8000, all under a Rule 10b5-1 trading plan.BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific TimeA BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%
Nancy Johnson liquidated 801 shares via a pre-established Rule 10b5-1 plan, retaining a $2.6 million stake in the molecular diagnostics firm.BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BillionToOne
Sign Up For FreeTo access detailed company insights
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. Billio... Read More
